ArticleJournal of neurological surgery. Part B, Skull base2026
Reduction of Cerebrospinal Fluid Leaks in Idiopathic Intracranial Hypertension with Glucagon-like Peptide-1 Receptor Agonist Use.
Article in Journal of neurological surgery. Part B, Skull base, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Risk Reduction of Recurrent Cerebrospinal Fluid Leaks With Postoperative Intracranial Pressure Management: A Systematic Review.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Elevated intracranial pressure (ICP) secondary to idiopathic intracranial hypertension (IIH) is a recognized risk factor for anterior and lateral skull base cerebrospinal fluid (CSF) leaks. A recent randomized controlled trial (Mitchell et al) demonstrated a significant reduction of ICP in IIH with the use glucagon-like peptide-1 (GLP-1) receptor agonists. This retrospective population study aims to evaluate the role of GLP-1 agonists in reducing CSF leaks. Design: Retrospective cohort database study. Setting: A collaborative global database (TriNetX) sourced from electronic medical records from 99 large healthcare organizations across the world. Participants: Adults (≥18 years old) with a diagnosis of IIH, stratified into groups based on the presence or absence of concurrent GLP-1 agonist use. Main Outcome Measures: The rate of spontaneous cranial CSF leak and the rate of anterior/lateral skull base CSF leak repair between GLP-1 users versus non-users over 3 years. Results: Compared with IIH patients not taking GLP-1 agonists ( Conclusions: GLP-1 agonist use in IIH patients is associated with a lower incidence of spontaneous cranial CSF leaks and a decreased rate of undergoing anterior and/or lateral skull base CSF leak repairs. These promising findings suggest that GLP-1 agonists may be an effective adjuvant therapeutic agent in preventing recurrence following CSF leak repair in IIH patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.